Montana has taken a bold step towards becoming a hub for experimental medical treatments. Any biotech company can now apply to sell drugs that have undergone preliminary testing—sometimes in as few as ten individuals—to consumers who provide informed consent and are willing to pay up to $12,500.

The first of these clinics is expected to open by the end of this year, offering treatments for rare diseases and those interested in preventive therapies. Critics argue that such a move could be dangerous, lacking oversight from the FDA.

Montana's law stands out as it extends access beyond terminally ill patients, emphasizing preventative medicine and longevity. The state’s Department of Health and Human Services has finalized rules to implement this new framework, ensuring informed consent but raising concerns about safety and ethics.

The involvement of Niklas Anzinger and the Alliance for Longevity Initiatives adds an intriguing layer. An entrepreneur focused on radical life extension, he sees Montana as a better model due to its regulatory precedents. With these rules in place, Montana is poised to become a unique testing ground for experimental treatments.